Genoa Pharmaceuticals said today that it raised $62 million in a Series A round to support the development of inhaled therapies for idiopathic pulmonary fibrosis and other severe pulmonary conditions. The round was led by F-Prime Capital Partners and Edmond de Rothschild Investment Partners.
Novo AS, RiverVest Venture Partners and TPG Biotech also invested in the round. The Seattle-based biotech added that venture capitalists Dr. Ketan Patel, Dr. Naveed Siddiqi, Tiba Aynechi, Niall O’Donnell and Dr. Heather Preston joined the baord of directors.
Dr. Bruce Montgomery was named CEO and the company’s founder, Mark Surber, was appointed chief scientific officer.
Get the full story at our sister site, Drug Delivery Business News.
The post Genoa raises $62m Series A for inhaled lung drug appeared first on MassDevice.